Literature DB >> 24390236

Missense mutations (p.H371Y, p.D438Y) in gene CHEK2 are associated with breast cancer risk in women of Balochistan origin.

Abdul Hameed Baloch1, Shakeela Daud, Nafeesa Raheem, Muhammad Luqman, Adeel Ahmad, Abdul Rehman, Jameela Shuja, Saeeda Rasheed, Akhtar Ali, Naseebullah Kakar, Hafiz Khush Naseeb, Mohammad Alam Mengal, Muhammad Arif Awan, Muhammad Wasim, Dost Mohammad Baloch, Jamil Ahmad.   

Abstract

CHEK2 encodes a serine/threonine-protein kinase which plays a critical role in DNA damage signaling pathways. CHEK2 directly phosphorylates and regulates the functions of p53 and BRCA1. Most women with breast and/or ovarian cancer are not carriers of mutant BRCA1 or BRCA2. Multiple studies have shown that a CHEK2*1100delC confers about a two-fold increased risk of breast cancer in unselected females and a tenfold increase in males. Moreover, studies have shown that first-degree relatives of bilateral breast cancer cases who carried the CHEK2*1100delC allele had an eight-fold increased risk of breast cancer. It has been suggested that CHEK2 functions as a low-penetrance susceptibility gene for cancers and multiplies the risks associated with other gene(s) to increase cancer risk. The main goal of this study was to evaluate and to compare the role of truncating mutations, splice junction mutations and rare missense substitutions in breast cancer susceptibility gene CHEK2. Present study was performed on 140 individuals including 70 breast cancer patients both with and without family history and 70 normal individuals. Written consent was obtained and 3 ml intravenous blood was drawn from all the subjects. DNA was extracted from all the samples through inorganic method published already. Primers were synthesized for all the 14 exons of CHEK2 gene. Coding and adjacent intronic sequences of CHEK2 gene were amplified and sequenced. Two genetic variants (p.H371Y, p.D438Y) were found in exon 10 and exon 11 of gene CHEK2 which were not found in any of the 70 control individuals from same geographical area and ethnic group. The genetic variant c.1312G>T (p.D438Y) identified in a patient with a family history of breast cancer. To our knowledge, this is first mutation scanning study of gene CHEK2 from Balochistan population.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24390236     DOI: 10.1007/s11033-013-2956-x

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  29 in total

Review 1.  The DNA damage response: putting checkpoints in perspective.

Authors:  B B Zhou; S J Elledge
Journal:  Nature       Date:  2000-11-23       Impact factor: 49.962

2.  A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer.

Authors:  Pia Vahteristo; Jirina Bartkova; Hannaleena Eerola; Kirsi Syrjäkoski; Salla Ojala; Outi Kilpivaara; Anitta Tamminen; Juha Kononen; Kristiina Aittomäki; Päivi Heikkilä; Kaija Holli; Carl Blomqvist; Jiri Bartek; Olli-P Kallioniemi; Heli Nevanlinna
Journal:  Am J Hum Genet       Date:  2002-07-28       Impact factor: 11.025

Review 3.  Cell-cycle checkpoints and cancer.

Authors:  Michael B Kastan; Jiri Bartek
Journal:  Nature       Date:  2004-11-18       Impact factor: 49.962

4.  Breast cancer in pakistan - awareness and early detection.

Authors:  Saba Sohail; Shams Nadeem Alam
Journal:  J Coll Physicians Surg Pak       Date:  2007-12       Impact factor: 0.711

5.  Pattern of breast cancer: experience at Lady Reading Hospital, Peshawar.

Authors:  Muhammad Naeem; Nadim Khan; Zahid Aman; Amir Nasir; Ambreen Samad; Abbas Khattak
Journal:  J Ayub Med Coll Abbottabad       Date:  2008 Oct-Dec

6.  Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations.

Authors:  Hanne Meijers-Heijboer; Ans van den Ouweland; Jan Klijn; Marijke Wasielewski; Anja de Snoo; Rogier Oldenburg; Antoinette Hollestelle; Mark Houben; Ellen Crepin; Monique van Veghel-Plandsoen; Fons Elstrodt; Cornelia van Duijn; Carina Bartels; Carel Meijers; Mieke Schutte; Lesley McGuffog; Deborah Thompson; Douglas Easton; Nayanta Sodha; Sheila Seal; Rita Barfoot; Jon Mangion; Jenny Chang-Claude; Diana Eccles; Rosalind Eeles; D Gareth Evans; Richard Houlston; Victoria Murday; Steven Narod; Tamara Peretz; Julian Peto; Catherine Phelan; Hong Xiang Zhang; Csilla Szabo; Peter Devilee; David Goldgar; P Andrew Futreal; Katherine L Nathanson; Barbara Weber; Nazneen Rahman; Michael R Stratton
Journal:  Nat Genet       Date:  2002-04-22       Impact factor: 38.330

7.  Various aspects, patterns and risk factors in breast cancer patients of Balochistan.

Authors:  Abdul Hameed Baloch; Jameela Shuja; Shakeela Daud; Muneer Ahmed; Adeel Ahmad; Mehrullah Tareen; Farah Khan; Muhammad Azam Kakar; Dost Mohammad Baloch; Naseebullah Kakar; Hafiz Khush Naseeb; Jamil Ahmad
Journal:  Asian Pac J Cancer Prev       Date:  2012

8.  Rare, evolutionarily unlikely missense substitutions in CHEK2 contribute to breast cancer susceptibility: results from a breast cancer family registry case-control mutation-screening study.

Authors:  Florence Le Calvez-Kelm; Fabienne Lesueur; Francesca Damiola; Maxime Vallée; Catherine Voegele; Davit Babikyan; Geoffroy Durand; Nathalie Forey; Sandrine McKay-Chopin; Nivonirina Robinot; Tù Nguyen-Dumont; Alun Thomas; Graham B Byrnes; John L Hopper; Melissa C Southey; Irene L Andrulis; Esther M John; Sean V Tavtigian
Journal:  Breast Cancer Res       Date:  2011-01-18       Impact factor: 6.466

9.  Family history, genetic testing, and clinical risk prediction: pooled analysis of CHEK2 1100delC in 1,828 bilateral breast cancers and 7,030 controls.

Authors:  Olivia Fletcher; Nichola Johnson; Isabel Dos Santos Silva; Outi Kilpivaara; Kristiina Aittomäki; Carl Blomqvist; Heli Nevanlinna; Marijke Wasielewski; Hanne Meijers-Heijerboer; Annegien Broeks; Marjanka K Schmidt; Laura J Van't Veer; Michael Bremer; Thilo Dörk; Elena V Chekmariova; Anna P Sokolenko; Evgeny N Imyanitov; Ute Hamann; Muhammad U Rashid; Hiltrud Brauch; Christina Justenhoven; Alan Ashworth; Julian Peto
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-01       Impact factor: 4.254

10.  CHEK2 variants associate with hereditary prostate cancer.

Authors:  E H Seppälä; T Ikonen; N Mononen; V Autio; A Rökman; M P Matikainen; T L J Tammela; J Schleutker
Journal:  Br J Cancer       Date:  2003-11-17       Impact factor: 7.640

View more
  9 in total

1.  Germline variants in pancreatic cancer patients with a personal or family history of cancer fulfilling the revised Bethesda guidelines.

Authors:  Akihiro Ohmoto; Chigusa Morizane; Emi Kubo; Erina Takai; Hiroko Hosoi; Yasunari Sakamoto; Shunsuke Kondo; Hideki Ueno; Kazuaki Shimada; Shinichi Yachida; Takuji Okusaka
Journal:  J Gastroenterol       Date:  2018-04-17       Impact factor: 7.527

2.  A novel recurrent CHEK2 Y390C mutation identified in high-risk Chinese breast cancer patients impairs its activity and is associated with increased breast cancer risk.

Authors:  N Wang; H Ding; C Liu; X Li; L Wei; J Yu; M Liu; M Ying; W Gao; H Jiang; Y Wang
Journal:  Oncogene       Date:  2015-01-26       Impact factor: 9.867

Review 3.  Current perspectives on CHEK2 mutations in breast cancer.

Authors:  Panagiotis Apostolou; Ioannis Papasotiriou
Journal:  Breast Cancer (Dove Med Press)       Date:  2017-05-12

4.  Computational analysis of high-risk SNPs in human CHK2 gene responsible for hereditary breast cancer: A functional and structural impact.

Authors:  Nutan V Badgujar; Bhoomi V Tarapara; Franky D Shah
Journal:  PLoS One       Date:  2019-08-09       Impact factor: 3.240

5.  A multicenter study assessing the prevalence of germline genetic alterations in Chinese gastric-cancer patients.

Authors:  Yin-Jie Zhang; Yang Yang; Qing Wei; Ting Xu; Xiao-Tian Zhang; Jing Gao; Si-Yi Tan; Bao-Rui Liu; Jing-Dong Zhang; Xiao-Bing Chen; Zhao-Jie Wang; Meng Qiu; Xin Wang; Lin Shen; Xi-Cheng Wang
Journal:  Gastroenterol Rep (Oxf)       Date:  2021-05-29

6.  Germline Testing in a Cohort of Patients at High Risk of Hereditary Cancer Predisposition Syndromes: First Two-Year Results from South Italy.

Authors:  Francesco Paduano; Emma Colao; Fernanda Fabiani; Valentina Rocca; Francesca Dinatolo; Adele Dattola; Lucia D'Antona; Rosario Amato; Francesco Trapasso; Francesco Baudi; Nicola Perrotti; Rodolfo Iuliano
Journal:  Genes (Basel)       Date:  2022-07-21       Impact factor: 4.141

7.  A unified analytic framework for prioritization of non-coding variants of uncertain significance in heritable breast and ovarian cancer.

Authors:  Eliseos J Mucaki; Natasha G Caminsky; Ami M Perri; Ruipeng Lu; Alain Laederach; Matthew Halvorsen; Joan H M Knoll; Peter K Rogan
Journal:  BMC Med Genomics       Date:  2016-04-11       Impact factor: 3.063

Review 8.  Breast cancer protection by genomic imprinting in close kin families.

Authors:  Srdjan Denic; Mukesh M Agarwal
Journal:  BMC Med Genet       Date:  2017-11-21       Impact factor: 2.103

9.  Study on the Mechanism of Cell Cycle Checkpoint Kinase 2 (CHEK2) Gene Dysfunction in Chemotherapeutic Drug Resistance of Triple Negative Breast Cancer Cells.

Authors:  Li Luo; Wei Gao; Jinghui Wang; Dingxue Wang; Xiaobo Peng; Zhaoyang Jia; Ye Jiang; Gongzhuo Li; Dongxin Tang; Yajie Wang
Journal:  Med Sci Monit       Date:  2018-05-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.